{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:51:04Z","timestamp":1782453064992,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T00:00:00Z","timestamp":1484611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Capital Medical Development Research Foundation","award":["2009-2025"],"award-info":[{"award-number":["2009-2025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40266-016-0431-9","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T12:22:18Z","timestamp":1484655738000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Meropenem Dosing Based on a Population Pharmacokinetic\u2013Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract"],"prefix":"10.1007","volume":"34","author":[{"given":"Qing-Tao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"issue":"Suppl 2","key":"431_CR1","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Suppl 2):S266\u201375.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"431_CR2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/11595960-000000000-00000","volume":"28","author":"QT Zhou","year":"2011","unstructured":"Zhou QT, He B, Zhang C, et al. Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging. 2011;28(11):903\u201312.","journal-title":"Drugs Aging"},{"issue":"3","key":"431_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/jcph.600","volume":"56","author":"MG Kees","year":"2016","unstructured":"Kees MG, Minichmayr IK, Moritz S, et al. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J Clin Pharmacol. 2016;56(3):307\u201315.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"431_CR4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/jac\/dku429","volume":"70","author":"A Ramon-Lopez","year":"2015","unstructured":"Ramon-Lopez A, Allen JM, Thomson AH, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother. 2015;70(3):882\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"431_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2050-6511-15-21","volume":"15","author":"J Goncalves-Pereira","year":"2014","unstructured":"Goncalves-Pereira J, Silva NE, Mateus A, et al. Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol. 2014;15:21.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"431_CR6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2710.2010.01171.x","volume":"36","author":"T Muro","year":"2011","unstructured":"Muro T, Sasaki T, Hosaka N, et al. Population pharmacokinetic analysis of meropenem in Japanese adult patients. J Clin Pharm Ther. 2011;36(2):230\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"431_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1128\/AAC.02029-13","volume":"58","author":"SH Macvane","year":"2014","unstructured":"Macvane SH, Crandon JL, Nicolau DP. Characterizing in vivo pharmacodynamics of carbapenems against Acinetobacter baumannii in a murine thigh infection model to support breakpoint determinations. Antimicrob Agents Chemother. 2014;58(1):599\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"431_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","volume":"70","author":"F Frippiat","year":"2015","unstructured":"Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015;70(1):207\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"431_CR9","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dku150","volume":"69","author":"C Feh\u00e9r","year":"2014","unstructured":"Feh\u00e9r C, Rovira M, Soriano A, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother. 2014;69(9):2556\u201362.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"431_CR10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1128\/AAC.43.3.681","volume":"43","author":"B Byl","year":"1999","unstructured":"Byl B, Jacobs F, Roucloux I, et al. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother. 1999;43(3):681\u20132.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"431_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"10","key":"431_CR12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"issue":"Suppl 6","key":"431_CR13","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"17","author":"M Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1\u201359.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"431_CR14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society; Infectious Diseases Society of America","year":"2005","unstructured":"American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"431_CR15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","volume":"36","author":"TC Horan","year":"2008","unstructured":"Horan TC, Andrus M, Dudeck MA. CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309\u201332.","journal-title":"Am J Infect Control"},{"key":"431_CR16","volume-title":"Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-third informational supplement. M100-S23. Wayne: CLSI; 2013."},{"issue":"8","key":"431_CR17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"431_CR18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","volume":"56","author":"JM Dulhunty","year":"2013","unstructured":"Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236\u201344.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"431_CR19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent \u03b2-Lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016;194(6):681\u201391.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"431_CR20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535\u201345.","journal-title":"Intensive Care Med"},{"issue":"3","key":"431_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1099\/jmm.0.000214","volume":"65","author":"M Tsala","year":"2016","unstructured":"Tsala M, Vourli S, Kotsakis S, et al. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications. J Med Microbiol. 2016;65(3):211\u20138.","journal-title":"J Med Microbiol"},{"issue":"9","key":"431_CR22","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1128\/AAC.00787-15","volume":"59","author":"P Cojutti","year":"2015","unstructured":"Cojutti P, Maximova N, Pea F. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients. Antimicrob Agents Chemother. 2015;59(9):5535\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"431_CR23","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s40262-015-0266-2","volume":"54","author":"MP Pai","year":"2015","unstructured":"Pai MP, Cojutti P, Pea F. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections. Clin Pharmacokinet. 2015;54(9):933\u201341.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"431_CR24","first-page":"1283","volume":"96","author":"S Jaruratanasirikul","year":"2013","unstructured":"Jaruratanasirikul S, Kositpantawong N, Jullangkoon M, et al. Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia. J Med Assoc Thai. 2013;96(10):1283\u20139.","journal-title":"J Med Assoc Thai"},{"issue":"11","key":"431_CR25","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.clinthera.2009.11.026","volume":"31","author":"A Kim","year":"2009","unstructured":"Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009;31(11):2765\u201378.","journal-title":"Clin Ther"},{"issue":"5","key":"431_CR26","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","volume":"51","author":"C Li","year":"2007","unstructured":"Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51(5):1725\u201330.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0431-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0431-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0431-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:16:39Z","timestamp":1568726199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0431-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0431-9","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]}}}